The Peptide CDMO (Pharmaceutical) Market Size is valued at 2173.44 Million in 2022 and is predicted to reach 4784.50 Million by the year 2031 at a 9.3 % CAGR during the forecast period for 2023-2031.
Peptides are bioactive molecules that bind to specific cell surface receptors, such as G protein-coupled receptors (GPCRs) or ion channels, where they trigger intracellular effects. Peptides have characteristics like safety, high specificity, and targeted drug delivery which are expected to create the future potential of expanding peptide therapeutics business. Increasing clinical demand for peptides favours the business of CDMOs.
Major driving factors of the peptide CDMO (pharmaceutical) market are the growing clinical applications of peptides, advancements in medical technologies, surging investments by pharma companies in peptides to develop drug therapies, increasing cases of chronic diseases, and a growing number of health-conscious people. Several drug developing industries outsource their peptide production operations to CDMOs (contract research, development and manufacturing organization) to achieve better operational efficiency and flexibility, which is projected to propel the growth of the peptide CDMO (pharmaceutical) market in the coming years. However, the high cost of outsourced services and the need for specialized expertise for peptide production may restrict the market growth during the projected period.
Market Segmentation
The peptide CDMO (pharmaceutical) market is segmented based on the scale of operation, method used, applications, synthesis types, and region. The scale of operation segment comprises preclinical/clinical and commercial. By method used, the market is classified into chemical synthesis method and non-chemical synthesis method. The market is segmented into peptide supplements, peptide vaccines, peptides as radio-theranostic agents, cell-penetrating peptides (CPPs), affinity ligands, and protein mimics based on applications. The market is divided into LPPS (Liquid-phase Peptide Synthesis), SPPS (Solid-phase Peptide Synthesis), and Mixed Phase by synthesis types. SPPS segment is expected to dominate this market over the forecast period. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, & the Middle East and Africa.
Competitive Landscape
Some Of The Key Players Operating In The Peptide CDMO (Pharmaceutical) Market
- AmbioPharm,
- Auspep,
- Bachem,
- BCN Peptide,
- CPC Scientific,
- CBL- Chemical and Biopharmaceutical Laboratories,
- Creative Peptides,
- Chinese Peptide,
- CSBio,
- Corden Pharma,
- PolyPeptide,
- Hybio Pharmaceutical,
- Peptide Institute,
- Pepscan,
- Almac,
- Vivitide,
- CreoSalus Inc,
- ScinoPharm,
- Senn Chemicals,
- Wuxi AppTec,
- Olon,
- Belyntic,
- Ferring Pharma,
- Numaferm,
- Hybio Pharmaceutical,
- Provepharm Life Solutions,
- Enzene Biosciences,
- Ardena Holding,
- Stelis Biopharma,
- Piramal Pharma,
- Space Peptides Pharmaceutical
Peptide CDMO (Pharmaceutical) Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 2173.44 Million |
|
Revenue Forecast In 2031 |
USD 4784.50 Million |
|
Growth Rate CAGR |
CAGR of 9.3 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Scale of Operation, Method Used, Applications, Synthesis Types, |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
AmbioPharm, Auspep, Bachem, BCN Peptide, CPC Scientific, CBL- Chemical and Biopharmaceutical Laboratories, Creative Peptides, Chinese Peptide, CSBio, Corden Pharma, PolyPeptide, Hybio Pharmaceutical, Peptide Institute, Pepscan, Almac, Vivitide, CreoSalus Inc, ScinoPharm, Senn Chemicals, Wuxi AppTec, Olon, Belyntic, Ferring Pharma, Numaferm, Hybio Pharmaceutical, Provepharm Life Solutions, Enzene Biosciences, Ardena Holding, Stelis Biopharma, Piramal Pharma, Space Peptides Pharmaceutical, and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
